我的生活+的主要目标之一是帮助人们预防新的HIV和其他STI,丙型肝炎和结核病病历的产生。

该应用程序有助于建立医生和HIV感染者之间的匿名沟通。 它可以让您创建简单易行的服药时间表,并设置隐藏和个性化的提醒。

返回
4 七月 2017, 09:55
1022

Ibalizumab Was Granted a Priority Rewiev by the FDA

Ibalizumab Was Granted a Priority Rewiev by the FDA - 图片 1

The application for a biologics license for the ibalizumab (an investigational monoclonal antibody) was accepted by the FDA. Next winter the drug is planned to be available in the american drugstores. Potentially ibalizumab is new treatment for multidrug-resistant HIV, according to a press release.

Approximately more than 20 000 americans with HIV-positive status have treatment resistance to at least one drug. Ibalizumab may become the first ART with a brand new way of action in almost 10 years and the only treatment that does not need to be taken daily.

“We are excited to be one step closer to potentially bringing an important new treatment, with a new mechanism of action, to patients whose virus has become resistant to therapies in multiple classes and have limited treatment options for the long-term management of their condition. The granting of priority review status is important since it confirms that, if approved, ibalizumab would represent a significant improvement in the treatment of this serious condition.” - the president and CEO of Theratechnologies Inc., a partner company of TaiMed Biologics, Luc Tanguay, commented the results of the research.

作者: Marina Shegay

在社交媒体上分享